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Abstract
Background: Indigenous children in Australia and Alaska have very high rates of chronic suppurative lung disease (CSLD)/
bronchiectasis. Antibiotics, including frequent or long-term azithromycin in Australia and short-term beta-lactam therapy in
both countries, are often prescribed to treat these patients. In the Bronchiectasis Observational Study we examined over
several years the nasopharyngeal carriage and antibiotic resistance of respiratory bacteria in these two PCV7-vaccinated
populations.
Methods: Indigenous children aged 0.5–8.9 years with CSLD/bronchiectasis from remote Australia (n = 79) and Alaska
(n = 41) were enrolled in a prospective cohort study during 2004–8. At scheduled study visits until 2010 antibiotic use in the
preceding 2-weeks was recorded and nasopharyngeal swabs collected for culture and antimicrobial susceptibility testing.
Analysis of respiratory bacterial carriage and antibiotic resistance was by baseline and final swabs, and total swabs by year.
Results: Streptococcus pneumoniae carriage changed little over time. In contrast, carriage of Haemophilus influenzae declined
and Staphylococcus aureus increased (from 0% in 2005–6 to 23% in 2010 in Alaskan children); these changes were associated
with increasing age. Moraxella catarrhalis carriage declined significantly in Australian, but not Alaskan, children (from 64% in
2004–6 to 11% in 2010). While beta-lactam antibiotic use was similar in the two cohorts, Australian children received more
azithromycin. Macrolide resistance was significantly higher in Australian compared to Alaskan children, while H. influenzae
beta-lactam resistance was higher in Alaskan children. Azithromycin use coincided significantly with reduced carriage of S.
pneumoniae, H. influenzae and M. catarrhalis, but increased carriage of S. aureus and macrolide-resistant strains of S.
pneumoniae and S. aureus (proportion of carriers and all swabs), in a ‘cumulative dose-response’ relationship.
Conclusions: Over time, similar (possibly age-related) changes in nasopharyngeal bacterial carriage were observed in
Australian and Alaskan children with CSLD/bronchiectasis. However, there were also significant frequency-dependent
differences in carriage and antibiotic resistance that coincided with azithromycin use.
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Introduction
Indigenous children in Australia, Alaska and New Zealand have
amongst the world’s highest recorded rates of chronic suppurative
lung disease (CSLD), including bronchiectasis unrelated to cystic
fibrosis (CF) [1]. Antibiotics play a key role in managing persistent
respiratory symptoms and acute exacerbations associated with
bronchiectasis [2]. However, few longitudinal data exist on the
impact of antibiotics upon the airway bacteriology of these patients.
This is an important knowledge gap as Indigenous children have
high rates of nasopharyngeal bacterial carriage [3] and micro-
aspiration of upper airway bacteria may contribute to both the
pathogenesis and on-going morbidity of bronchiectasis [4].
Based upon the clinical impression that patients receiving
azithromycin have fewer acute respiratory exacerbations, there is
anecdotal evidence that many clinicians in Australia routinely
prescribe azithromycin (frequently long-term) for children with
bronchiectasis, while in Alaska such practice is uncommon. In
contrast, both sites utilize short-term intermittent therapy with
beta-lactam antibiotics (e.g. amoxicillin or amoxicillin-clavulanate)
for acute pulmonary exacerbations associated with bronchiectasis.
The Bronchiectasis Observational Study was established in
Australia and Alaska to study prospectively the clinical course of
CSLD/bronchiectasis in Indigenous children [1]. Using the
opportunity thus provided, we examined the nasopharyngeal
carriage of respiratory bacteria and their antibiotic resistance
patterns in children. We hypothesised that the two populations
would differ in their nasopharyngeal carriage of potential
respiratory bacterial pathogens and antibiotic resistance in these
organisms as a result of differences in prescribing practices
between the two settings.
Methods
Subjects
Children 0.5–8.9 years of age with a diagnosis of non-CF
bronchiectasis (confirmed on high-resolution computerized to-
mography) or chronic (.3-months) daily wet (or productive) cough
were enrolled in a prospective cohort study during 2004–8 [1].
Children were recruited opportunistically while attending an
outpatient clinic or in hospital undergoing bronchoscopy for
suspected CSLD/bronchiectasis or for respiratory exacerbations.
Subsequently, enrolled children were examined and nasopharyn-
geal swabs collected by research staff at scheduled study visits until
2010. These visits were scheduled quarterly in Australia (to ensure
at least one annual review in highly mobile enrolled children) and
annually in Alaska. Such visits were planned independently of the
children’s health status. Only visits where swabs were collected
were included in this analysis. Children’s vaccination status at
baseline was recorded from immunisation registers. Antibiotic use
in the 2-weeks preceding swab collection (to capture recent
antibiotic events and allow comparison with other studies in this
population [5] and studies using parent recall) was recorded from
clinic notes.
Ethics statement
The study was approved by the Human Research Ethics
Committee of the Northern Territory Department of Health and
Menzies School of Health Research in Australia (HREC 04/46)
and the Alaska Area Institutional Review Board (which acts under
the Indian Health Service Institutional Review Board FWA
number 0008894). At enrolment written informed consent was
obtained from the carer of each child and when appropriate assent
was also provided by the older children in the cohort. The process
of obtaining consent, and the information sheets and consent
forms used (stored securely at each research institute), were
approved by the respective ethics bodies.
Specimen collection and laboratory testing
Nasopharyngeal swabs collected at study visits were transported
and processed according to published methods [5,6], unless
otherwise noted. Swabs stored in skim-milk tryptone glucose
glycerol broth at 280uC were thawed and 10 mL aliquots plated
on selective media and incubated overnight at 37uC and 5% CO2.
In Australia, four colonies each (including any with differing
morphologies) of presumptive Streptococcus pneumoniae and Haemoph-
ilus influenzae, two of Moraxella catarrhalis and one of Staphylococcus
aureus were isolated and identified using standard methods [5]. In
Alaska, multiple colonies were picked when differing morphologies
were observed. When multiple isolates underwent antibiotic
susceptibility testing, the child was reported as carrying a resistant
strain if one or more of the isolates proved resistant. S. pneumoniae
serotypes were determined by the Quellung reaction using antisera
from Statens Serum Institute (Denmark).
Antimicrobial sensitivities for S. pneumoniae, H. influenzae and S.
aureus isolates were determined by disk diffusion (Australia [7];
Alaska [8]). Minimum inhibitory concentrations (MICs) were
determined for resistant S. pneumoniae and H. influenzae isolates
using Etest strips (AB bioMe´rieux, France) in Australia. In Alaska,
erythromycin and penicillin MICs for S. pneumoniae were deter-
mined by microbroth dilution and ampicillin MICs for H.
influenzae were determined using Etest strips. MIC breakpoints
from the European Committee on Antimicrobial Susceptibility
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Testing (EUCAST, http://www.eucast.org) were used to define
resistance for S. pneumoniae (penicillin resistance MIC.2 mg/L,
intermediate resistance MIC.0.06–2 mg/L; macrolide [azithro-
mycin or erythromycin] resistance MIC.0.5 mg/L) and H.
influenzae (ampicillin resistance MIC.1 mg/L; macrolide resis-
tance MIC.4 mg/L, intermediate resistance MIC.0.12–4 mg/
L). A nitrocephin-based test detected beta-lactamase activity in H.
influenzae and M. catarrhalis isolates.
Data analysis
Carriage data are reported as the proportion of children at
baseline (first swab) and as they left the study (last swab), and also
presented graphically as the proportion of total swabs collected per
study year. As storage of 29 swabs from Central Australia during
2004–6 was at 220uC, which is suboptimal for recovery of H.
influenzae [9], these samples were excluded from analyses involving
this pathogen and the first subsequent swab for each child was
included for H. influenzae baseline data. Also, as only 20 swabs were
collected from both cohorts in 2004–5, their data were combined
with those from 2006.
Antibiotic resistance data are reported as the proportion of
carriers as children entered and left the study, proportion of total
isolates for each bacterial species, and graphically as the
proportion of all positive swabs by study year. Multiple strains
detected in the same swab (differing serotype or antibiotype for S.
pneumoniae and H. influenzae, differing beta-lactamase status for M.
catarrhalis) were counted as additional isolates where results for
total isolates are presented.
Confidence intervals (CIs) were calculated using the exact
binomial method for first and last swabs from each child and
where numbers were small (,5), and otherwise adjusted for
repeated sampling using the clustered sandwich estimator for
estimating the variance-covariance matrix, implemented as
vce(cluster id) in Stata. We used Stata’s logistic command for
bivariate and multivariate analyses, and nptrend to test for trend
across ordered groups. Statistical tests were performed using Stata
12 (College Station, Texas).
To investigate the cumulative effect of repeated and sustained
long-term azithromycin exposure on bacterial carriage and
resistance, Australian children were divided into three groups
based on frequency of azithromycin use during the study period:
Azi-None = no azithromycin in the 2-weeks preceding swab
collection at any of the study visits; Azi-Infrequent = azithromy-
cin preceding 1–50% of study visits; Azi-Frequent = azithromycin
preceding .50% of study visits. Tables and figures are presented
as Supporting Information.
Results
Subjects
A total of 120 children were enrolled and 597 swabs collected
(Table 1). At enrolment, 24% of Alaskan and 30% of Australian
children had respiratory exacerbations. At subsequent visits the
numbers were 8% and 17% respectively. The mean number of
swabs collected per child per year enrolled (person-years of follow-
up) was 2.5 in Australia and 1.3 in Alaska. Most (88%) children had
received $3 doses of the 7-valent pneumococcal conjugate vaccine
(PCV7). In addition, two Australian children received $1 dose of
the pneumococcal Haemophilus influenzae protein D conjugate
vaccine introduced in 2009. No Alaskan children received
PCV13, introduced in 2010. Australian children were more likely
to receive azithromycin in the 2-weeks preceding swab collection,
while beta-lactam antibiotic use was similar in the two cohorts
(Table 1). There were no clear temporal trends in antibiotic use;
peaks were observed in beta-lactam antibiotic and azithromycin use
in 2007 and 2008 (preceding 18% and 55% of swabs collected
respectively) in Australian children, and in beta-lactam antibiotic
use in Alaskan children in 2008 (preceding 25% of swabs collected).
Nasopharyngeal carriage over time
Nasopharyngeal bacterial carriage as children entered and left
the study is shown in Table 2. Australian children were at
significantly lower risk than Alaskan children of M. catarrhalis
carriage at the study’s end, and this finding persisted after
adjusting for carriage at baseline. When all data were analysed as a
proportion of swabs by year (Figure 1), S. pneumoniae carriage
remained relatively stable, H. influenzae carriage declined in both
Australian (nptrend P= 0.007) and Alaskan (P= 0.033) children,
M. catarrhalis carriage in Australian children showed a marked
decline from 64% (95% CI 47–81) in 2004–6 to 11% (95% CI 2–
21) in 2010 (P,0.001), and S. aureus carriage in Alaskan children
increased from 0% (95% CI 0–9) in 2005–6 to 23% (95% CI 6–
40) in 2010 (P= 0.010).
Association between frequency of azithromycin use and
carriage
The number of children and time in the study were comparable
when Australian children were grouped by azithromycin exposure
Table 1. Enrolment, swab collection, vaccination and antibiotic use in Australian Indigenous and Alaska Native children.
Australia Alaska Total
Children enrolled 79 41 120
Median age at enrolment in years (range) 2.7 (0.8–8.9) 2.8 (0.5–7.9)
Person-years of follow-up 179 121 300
Median time in study in years (range) 2.2 (0–5.8) 3.4 (0–4.8)
Number of children who had received $3 doses of 7-valent PCV* at enrolment 71 (90%) 35 (85%) 106 (88%)
Swabs collected 443 154 597
Median number of swabs collected (range) 5 (1–15) 4 (1–11)
Number of swabs where children received antibiotics in the 2-weeks preceding collection:
Azithromycin 192 (43%) 1 (,1%) 193 (32%)
Beta-lactam antibiotics 44 (10%) 14 (9%) 58 (10%)
*Pneumococcal conjugate vaccine.
doi:10.1371/journal.pone.0070478.t001
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Figure 1. Pathogen carriage (proportion of swabs) by study year in Australian and Alaskan children.
doi:10.1371/journal.pone.0070478.g001
Table 2. Nasopharyngeal carriage of respiratory bacteria from Australian and Alaskan children at baseline and end of study.
First swab for each child Last swab for each child1
Australia Alaska Australia Alaska OR (95% CI)2
Children enrolled 79 41 76 37
Median age at study visit in years (range) 2.7 (0.8–8.9) 2.8 (0.5–7.9) 5.4 (1.7–13.0) 6.3 (2.1–11.8)
Number of male children 45 (57%) 22 (54%) 42 (55%) 19 (51%)
Nasopharyngeal carriage; n (%, 95% CI)
Streptococcus pneumoniae 47 (59, 48–70) 28 (68, 52–82) 44 (58, 46–69) 18 (49, 32–66) 1.45 (0.66–3.21)
Haemophilus influenza 47 (59, 48–70) 31 (76, 60–88) 32 (42, 31–54) 18 (49, 32–66) 0.81 (0.36–1.81)
Moraxella catarrhalis 38 (48, 37–60) 25 (61, 45–76) 22 (29, 19–40) 23 (62, 45–78) 0.25 (0.11–0.58)*
Staphylococcus aureus 6 (8, 3–16) 3 (7, 2–20) 11 (14, 7–24) 10 (27, 14–44) 0.46 (0.17–1.20)
Antibiotics received ,2 weeks before swab collection; n (%, 95% CI)
Macrolide 31 (39, 28–51) 0 (0, 0–9) 19 (25, 16–36) 0 (0, 0–9)
Beta-lactam 15 (19, 11–29) 3 (7, 2–20) 12 (16, 8–26) 1 (3, 0–14)
*P = 0.001; CI, confidence interval.
1Swabs from 7 children who only ever had one swab collected (included in baseline) were excluded.
2Multiple logistic regression compared carriage at the end of the study in Australian versus Alaskan children, adjusting for carriage at baseline.
doi:10.1371/journal.pone.0070478.t002
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(Table S1). However, there was a significant difference in the
frequency of visits by group: Azi-None: median 3.5 (range 1–10);
Azi-Infrequent: median 5 (range 2–14); Azi-Frequent: median 7
(range 1–15); nptrend P= 0.014. The median proportion of visits
at which children had received azithromycin was 33% (range 12–
50) in the Azi-Infrequent group and 75% (range 57–100) in the
Azi-Frequent group. Differences in bacterial carriage among these
groups were apparent at baseline. These differences were
accentuated by the end of the study and were significant for all
four bacteria (Table S1). A ‘cumulative dose-response’ relationship
was observed: increasing azithromycin use coincided with
decreasing carriage of S. pneumoniae, H. influenzae and M. catarrhalis,
and increasing carriage of S. aureus. The same trends were
apparent when data from all swabs were included (Figure S1,
nptrend P,0.001 for all four bacteria).
Since azithromycin use coincided with carriage differences in
the Australian children, carriage in the Alaskan children was
compared with carriage in the Australian Azi-None group.
Carriage of S. pneumoniae was higher in the Australian children,
while S. aureus carriage was higher in Alaskan children. These
differences were significant when all data were included; S.
pneumoniae and S. aureus carriage were 79% (95% CI 71–87) and
2% (95% CI 0–6) respectively in the Australian Azi-None group
compared to 60% (95% CI 52–67) and 15% (95% CI 9–21)
respectively in Alaskan children.
Antibiotic resistance
Resistance of bacterial pathogens as children entered and left
the study is shown in Table 3 and as a proportion of positive swabs
by year in Figure 2. No penicillin resistant S. pneumoniae isolates
(MIC.2 mg/L) were detected in either cohort. Macrolide
resistance in S. pneumoniae and S. aureus carriers was significantly
higher in Australian compared to Alaskan children. However,
beta-lactam antibiotic resistance was higher in Alaskan H.
influenzae carriers. Macrolide-resistant strains of S. pneumoniae and
S. aureus were also more prevalent in Australian children when all
swabs were included in analysis, isolated from 30% (95% CI 24–
36) and 14% (95% CI 9–20) of swabs respectively, compared to
4.5% (95% CI 1–8) and 4% (95% CI 0–8) respectively in Alaskan
children. H. influenzae and M. catarrhalis beta-lactam antibiotic
resistance were both higher in Alaskan children as a proportion of
all swabs: 19% (95% CI 13–26) had ampicillin-resistant H.
influenzae and 65% (95% CI 56–74) had beta-lactamase positive M.
catarrhalis strains compared to 4% (95% CI 2–6) and 29% (95% CI
23–35) respectively in Australian children.
Resistance as a proportion of all isolates is reported in Table 4.
All H. influenzae isolates from Alaskan children and 80% from
Australian children were macrolide-susceptible by disk diffusion.
Since most H. influenzae possess an intrinsic macrolide efflux
mechanism [10] which confers intermediate resistance by EU-
CAST criteria, MICs were determined for all Australian isolates.
Figure 2. Pathogen resistance (proportion of carriers) by study year in Australian and Alaskan children.
doi:10.1371/journal.pone.0070478.g002
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Association between frequency of azithromycin use and
resistance
Differences in bacterial resistance in the first and last swabs
from Australian children grouped by azithromycin exposure are
shown in Table S2. Macrolide resistance tended to be highest in
the Azi-Frequent group for S. pneumoniae, H. influenzae and S. aureus
carriers, but increased in S. pneumoniae in all three groups from the
beginning to the end of the study. When all swabs were included,
macrolide-resistant S. pneumoniae and S. aureus strains were found
in 21% (95% CI 14–28) and 1% (95% CI 0–5) respectively from
the Azi-None group, 28% (95% CI 17–38) and 14% (95% CI 6–
22) from the Azi-Infrequent group, and 38% (95% CI 26–49) and
23% (95% CI 14–33) from the Azi-Frequent group (nptrend
P= 0.002 and P,0.001 respectively). There were no trends for
beta-lactam antibiotic resistance in any of the four pathogens.
Trends by study year are shown in Figure S2.
S. pneumoniae and H. influenzae serotypes and resistance
patterns
Of 285 S. pneumoniae isolates serotyped from the Australian
children, PCV7 serotypes 19F and 23F were among the top 10
(Figure 3). The most prevalent serotype (8% of isolates) was 23B,
followed by 6A, 19A and 6C (each 7%), and 16F, 17F, 19F and
23F (each 6.5%). Of 96 isolates serotyped from the Alaskan
children the most prevalent serotype was 19A (15% of isolates)
followed by 23B (9%) and 3, 15A and 34 (each 6.5%). The
serotype hierarchy in Australian children appeared to coincide
with azithromycin use; serotypes that were prevalent in the Azi-
Frequent group also had the highest prevalence of azithromycin
resistance. Commonly carried macrolide-resistant serotypes in the
Australian group were 23B, 6A, 6C, 17F, 23F, 22F, 9N, 15A and
33D. In Alaskan children, azithromycin resistance was found in
only 7 isolates (5 different serotypes). Intermediate penicillin
resistance (MIC.0.06–2 mg/L) was most prevalent in serotypes
19A (100%), 19F, 23B (70% were both macrolide and interme-
diate penicillin resistant) and 16F in Australian children, and
serotypes 19A (67%) and 35B in Alaskan children. Multiple strains
were detected in 30 (12%) positive specimens (two had three
Table 3. Antibiotic resistance (proportion of carriers) in respiratory bacteria from Australian and Alaskan children at baseline and
end of study.
First swab for each child Last swab for each child
Australia Alaska Australia Alaska
Macrolide resistance; n (%, 95% CI)
MacR1 S. pneumoniae 17 (36, 23–51) 2 (7, 1–24)** 21 (48, 32–63) 2 (11, 1–35)**
AziIR2 H. influenzae 40 (85, 72–94) not determined3 304 (94, 79–99) not determined3
AziR2 H. influenzae 7 (15, 6–28) 0 (0, 0–11) 3 14 (3, 0–16) 0 (0, 0–19) 3
EryR5 S. aureus 5 (83, 36–100) 2 (67, 9–99) 10 (91, 59–100) 4 (40, 12–74)*
Beta-lactam antibiotic resistance; n (%, 95% CI)
PenIR6 S. pneumoniae 22 (47, 32–62) 6 (21, 8–41)* 18 (41, 26–57) 4 (22, 6–48)
AmpR7 H. influenzae 7 (15, 6–28) 9 (29, 14–48) 3 (9, 2–25) 6 (33, 13–59)*
BLpos8 H. influenzae 6 (13, 5–26) 9 (29, 14–48) 3 (9, 2–25) 6 (33, 13–59)*
BLpos8 M. catarrhalis 35 (92, 79–98) 25 (100, 86–100) 22 (100, 85–100) 23 (100, 85–100)
MethR9 S. aureus 3 (50, 12–88) 0 (0, 0–70) 1 (9, 0–41) 2 (20, 3–56)
*P,0.05, ** P,0.01 for difference in resistance between Australian and Alaskan carriers; CI, confidence interval.
1MacR, macrolide-resistant: azithromycin (Australia) and erythromycin (Alaska) minimum inhibitory concentration (MIC) .0.5 mg/L.
2AziIR, azithromycin intermediate resistant: MIC .0.12–4 mg/L; AziR, azithromycin resistant: MIC .4 mg/L for Australian children.
3All isolates from Alaskan children were susceptible on disk diffusion; MICs were not determined.
4Isolates from one swab did not grow on sensitivity plates.
5EryR, erythromycin resistant on disk diffusion.
6PenIR, penicillin intermediate resistant: MIC .0.06–2 mg/L; no resistant (MIC .2 mg/L) isolates were detected in either cohort.
7AmpR, ampicillin MIC .1 mg/L.
8BLpos, beta-lactamase positive.
9MethR, methicillin resistant on disk diffusion.
doi:10.1371/journal.pone.0070478.t003
Table 4. Antibiotic resistance as percentage (95% CI) of total
isolates in respiratory bacteria from Australian Indigenous and
Alaska Native children.
Australia Alaska
Streptococcus pneumoniae 285 isolates 96 isolates
Macrolide resistant1 49 (43–55) 7 (2–12)
Penicillin intermediate resistant2 33 (28–39) 21 (13–29)
Haemophilus influenzae 191 isolates 100 isolates
Azithromycin intermediate resistant3 90 (86–95) not determined
Azithromycin resistant 10 (5–14)4 0 (0–4)5
Ampicillin resistant6 11 (6–15) 32 (23–41)
Beta-lactamase positive 10 (6–14) 25 (17–33)
Moraxella catarrhalis 146 isolates 100 isolates
Beta-lactamase positive 88 (81–93) 100 (96–100)
Staphylococcus aureus 70 isolates 23 isolates
Erythromycin resistant5 91 (85–98) 26 (8–44)
Methicillin resistant5 17 (9–28) 13 (3–34)
CI, confidence interval.
1Azithromycin or erythromycin MIC.0.5 mg/L; 2MIC.0.06–2 mg/L;
3MIC.0.12–4 mg/L;
4MIC.4 mg/L; 5Resistant on disk diffusion; 6MIC.1 mg/L.
doi:10.1371/journal.pone.0070478.t004
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serotypes) from Australian children and four (4%) from Alaskan
children; this difference was likely due to more colonies being
selected in Australia. Overall, PCV7 serotypes comprised 13% of
Australian and 3% of Alaskan isolates.
Most H. influenzae isolates from both cohorts were nontypeable
(NTHi) (Australia 89% of 191 isolates, Alaska 83% of 100 isolates).
Capsular type b (Hib) was isolated from four children in both
cohorts (2% and 4% of isolates respectively); three (75%) Hib
isolates from Alaskan children were ampicillin resistant, but none
from Australian children. Using EUCAST criteria, three isolates
from Australian and eight from Alaskan children (three and seven
NTHi respectively, no Hib) were beta-lactamase negative, but
ampicillin resistant (BLNAR). However, only one BLNAR NTHi
isolate from an Alaskan child had ampicillin MIC$4 mg/L.
Multiple strains (different serotype and/or antibiotype) were
detected in 14% of Australian and 11% of Alaskan children.
Associations between age and other bacteria and
carriage
In bivariate analyses adjusted for repeated sampling of children,
age was significantly associated with carriage. Older children were
less likely to carry H. influenzae (Odds Ratio (OR) 0.91 per
additional year of age, 95% CI 0.83–0.99), but more likely to carry
S. aureus (OR 1.13 per additional year of age, 95% CI 1.01–1.25).
These associations largely remained when study year was included
in the analysis: OR 0.94 (95% CI 0.86–1.02) for H. influenzae and
OR 1.11 (95% CI 0.99–1.25) for S. aureus.
In multivariate analyses adjusted for the presence of other
respiratory bacteria and for repeated sampling of children, similar
associations were seen in both cohorts for S. pneumoniae coloniza-
tion, which was positively associated with H. influenzae (OR 3.18,
95% CI 2.07–4.88) and M. catarrhalis (OR 3.86, 95% CI 2.41–
6.19) and negatively associated with S. aureus (OR 0.38, 95% CI
0.21–0.70). Similar associations were also seen for H. influenzae
which was positively associated with the presence of M. catarrhalis
(OR 3.27, 95% CI 2.21–4.81), and for M. catarrhalis which was
negatively associated with S. aureus (OR 0.55, 95% CI 0.31–0.99).
Discussion
This is the first longitudinal study reporting nasopharyngeal
carriage in children with CSLD/bronchiectasis. While the two
patient populations described are distinct and geographically
dispersed, they share surprisingly similar environmental risk
factors [1]. Carriage of respiratory pathogens in these two
populations receiving different antibiotic treatment strategies
showed similarities, but also important differences. S. pneumoniae
carriage was similar overall and relatively stable in both Alaskan
and Australian children during the study period. Carriage of H.
influenzae declined in both cohorts over time, while S. aureus
carriage increased. Carriage of M. catarrhalis in Alaskan children
remained high throughout the study period, while carriage in
Australian children started at the same level, but declined
dramatically. Despite broadly similar carriage of three of the four
main bacteria in the two populations, azithromycin use in the
Australian cohort coincided with significant differences in the
carriage of all four organisms, with an apparent ‘cumulative dose-
response’ effect.
In the Australian Azi-None group, carriage of S. pneumoniae
(79% of all swabs) was equivalent to that previously reported in
this population [11]. Carriage of S. pneumoniae has been reported in
several populations to peak at 2–3 years of age and decline
Figure 3. Streptococcus pneumoniae serotype hierarchy (ordered by combined totals) for 79 Australian and 41 Alaskan children. NT,
nontypeable.
doi:10.1371/journal.pone.0070478.g003
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thereafter [12,13]. However, in Indigenous children and children
from developing countries, carriage is higher than in developed
countries and remains common up to 10-years of age [14,15]. In
the Azi-None group, carriage of H. influenzae was lower (60%) than
the 85% reported in a younger cohort of Indigenous children [3],
but similar to that reported for Aboriginal children 5–8 years of
age [14]. The observed decline in carriage in both cohorts may
therefore be age-related (as we found in bivariate analysis) as
children grew older during the study. M. catarrhalis carriage (63%)
in the Australian Azi-None group was lower than previously
reported, even in older Indigenous children [14]. Nevertheless, M.
catarrhalis carriage in this group and the Alaskan children was
higher than generally reported in healthy children or children with
upper respiratory tract infections [16].
S. aureus carriage has not been reported previously in this
Australian population, and Alaskan reports are from a community
with high rates of methicillin-resistant S. aureus infection [17]. In
other populations, S. aureus carriage is high in infants ,3-months
of age, but declines rapidly as carriage of the other three bacteria
increases, reaching a low point at 1–2 years [18,19]. Carriage then
increases again to reach its highest prevalence in children 6–
11 years of age [12,20]. If these trends apply to Australian and
Alaskan children, then S. aureus carriage could be expected to be
near its lowest point at the age when most of the children in this
study were enrolled and highest at the age when their last swabs
were collected. This would explain the observed increase in S.
aureus carriage over the study period in both cohorts.
Consistent with other studies [3,5], we found that azithromycin
use coincided with significant reductions in carriage of S.
pneumoniae, H. influenzae and M. catarrhalis in the Australian
children. Our study also found an apparent ‘cumulative dose
response’ effect on carriage and resistance. However, a potential
confounding factor was attendance at clinic, as children who did
not take azithromycin had fewer clinic attendances (fewer swabs
collected). While we cannot exclude the possibility that they only
attended clinic when they were sick and therefore more likely to be
carrying bacteria, most swabs were collected at scheduled visits
that were arranged independently of the child’s health status.
Factors other than azithromycin may also be involved in the
decline of M. catarrhalis carriage in Australian children, since this
decline was also seen in the Azi-None group. Conversely, while the
increase in S. aureus carriage in Alaskan children is most likely age-
related, the increase in Australian children may also be partly
attributable to azithromycin since no such increase was seen in the
Azi-None group (where S. pneumoniae carriage remained high).
Levels of macrolide resistance in bacteria colonizing the
Australian children were not only higher than in the Alaskan
children, but also higher than previously reported for most S.
pneumoniae and H. influenzae paediatric respiratory tract isolates
worldwide [10,21,22], and similar to the high levels of macrolide
resistance in S. aureus often found in CF patients treated with
azithromycin [23,24]. Levels of beta-lactam antibiotic resistance in
Alaskan children were similar to previous reports from North
America [21,22], and higher than H. influenzae and M. catarrhalis
(but not S. pneumoniae) beta-lactam antibiotic resistance in
Australian children. Beta-lactamase produced by one organism
may protect co-colonizing bacteria from beta-lactam antibiotics
[25,26]. However, we found conflicting evidence using simple
multivariate analyses (data not shown). The higher rates of
intermediate resistance to penicillin in Australian S. pneumoniae
isolates may be due to other factors, e.g. co-occurrence of
macrolide and intermediate penicillin resistance in prevalent
serotypes such as 23B.
As with other observational studies, it is possible that the
associations observed may be confounded by factors not measured.
Patients who took azithromycin consistently may differ from those
who did not. Antibiotics taken before enrolment likely affected
baseline carriage. Additionally, biases may have been introduced if
the carriage status of children for whom we achieved good follow-
up was systemically different to those for whom our follow-up was
less successful. The different swabbing schedules (quarterly in
Australia and annually in Alaska) may also have led to bias, e.g. if
carriage varied seasonally and children were mostly seen at a
particular time of year, or if resistant strains were persistently
carried by the same child. However, children from both cohorts
were seen in all months of the year, and a recent Kenyan study
found the mean duration of S. pneumoniae carriage to be just over
30-days [27]. Thus swabbing every 3-months is unlikely to detect
the same S. pneumoniae carriage episode, and this was confirmed by
inspection of our serotype data by child visit. However, without
further strain discrimination we cannot comment on carriage
duration in other species. Finally, while changes in H. influenzae
and S. aureus carriage over time appeared to be age-related,
differences could also be explained by other temporal changes.
In conclusion, this study adds important new information on
long-term carriage and antibiotic resistance trends in Indigenous
children with CSLD/bronchiectasis from two environmentally
diverse regions of the world. While similar, possibly age-related,
changes in carriage were observed over time in both patient
populations, azithromycin use was associated with a ‘cumulative
dose-dependent’ pattern of carriage and resistance in the
Australian children. Moreover, while two recent randomised
controlled trials showed that adults with non-CF bronchiectasis
had fewer respiratory exacerbations after receiving azithromycin
continuously for 6–12 month periods [28,29], this was accompa-
nied by increased macrolide resistance amongst respiratory
pathogens [29]. Such studies need to be repeated in children
and, in light of these findings in adults and our own studies in
children, special attention should be paid to monitoring antibiotic
resistance as this may ultimately offset any clinical benefit derived
from this important class of antibiotics.
Supporting Information
Figure S1 Pathogen carriage (proportion of swabs) by
study year in Australian and Alaskan children.1 1Austra-
lian children were grouped by proportion of study visits with
azithromycin use ,2-weeks before swab collection at: Azi-None
= no study visits; Azi-Infreq(uent) = 1–50% of study visits; Azi-
Freq(uent) = 51–100% of study visits.
(TIF)
Figure S2 Pathogen resistance (proportion of carriers)
by study year in Australian and Alaskan children.1
1Australian children were grouped by proportion of study visits
with azithromycin use ,2-weeks before swab collection at: Azi-
None = no study visits; Azi-Infreq(uent) = 1–50% of study visits;
Azi-Freq(uent) = 51–100% of study visits.
(TIF)
Table S1 Nasopharyngeal carriage of respiratory bac-
teria from Australian children, grouped by azithromycin
exposure1, at baseline and end of study. 1Australian
children were grouped by proportion of study visits with
azithromycin use ,2-weeks before swab collection at: Azi-None
= no study visits; Azi-Infreq(uent) = 1–50% of study visits; Azi-
Freq(uent) = 51–100% of study visits.
(DOC)
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Table S2 Antibiotic resistance (proportion of carriers)
in respiratory bacteria from Australian children,
grouped by azithromycin exposure1, at baseline and
end of study. 1Australian children were grouped by proportion
of study visits with azithromycin use ,2-weeks before swab
collection at: Azi-None = no study visits; Azi-Infreq(uent) = 1–
50% of study visits; Azi-Freq(uent) = 51–100% of study visits.
(DOC)
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